Atrás
Precio Agenus Inc (AGEN)
Gráfico del Precio de Acciones AGEN
AGEN Ganando
Agenus Inc
$3.34
-9.23%
$-0.34
Al cierre: Jan 16, 16:00:00 GMT-5
$3.39
1.79%
$0.05
Mercado Posterior: Jan 16, 20:00:00 GMT-5
Estadísticas clave
Cierre Anterior
$3.68
Precio de apertura
$3.76
Rango del día
$3.3 - $3.76
Rango de 52 semanas
$1.38 - $7.34
Volumen
1.7M
Volumen promedio
648.8K
EPS (TTM)
-2.84
Rendimiento de dividendos
--
Cap. de mercado
$115.6M
¿Qué es AGEN?
Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 316 full-time employees. The company went IPO on 2000-02-04. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Características
Estrategias de Trading
© 2025 Finture Development Limited. All rights reserved